KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $73.0 million.

  • Halozyme Therapeutics' Other Operating Expenses rose 865.63% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.1 million, marking a year-over-year increase of 930.5%. This contributed to the annual value of $230.5 million for FY2024, which is 1340.23% down from last year.
  • As of Q3 2025, Halozyme Therapeutics' Other Operating Expenses stood at $73.0 million, which was up 865.63% from $64.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' Other Operating Expenses' 5-year high stood at $75.2 million during Q3 2023, with a 5-year trough of $15.9 million in Q1 2022.
  • Moreover, its 5-year median value for Other Operating Expenses was $57.4 million (2024), whereas its average is $50.7 million.
  • Data for Halozyme Therapeutics' Other Operating Expenses shows a peak YoY increase of 30101.05% (in 2021) and a maximum YoY decrease of 1783.27% (in 2021) over the last 5 years.
  • Over the past 5 years, Halozyme Therapeutics' Other Operating Expenses (Quarter) stood at $21.6 million in 2021, then skyrocketed by 116.2% to $46.7 million in 2022, then surged by 50.11% to $70.1 million in 2023, then decreased by 14.62% to $59.8 million in 2024, then increased by 22.05% to $73.0 million in 2025.
  • Its Other Operating Expenses stands at $73.0 million for Q3 2025, versus $64.1 million for Q2 2025 and $66.2 million for Q1 2025.